TY - JOUR T1 - Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial JF - medRxiv DO - 10.1101/2020.04.29.20085761 SP - 2020.04.29.20085761 AU - Yan Lou AU - Lin Liu AU - Hangping Yao AU - Xingjiang Hu AU - Junwei Su AU - Kaijin Xu AU - Rui Luo AU - Xi Yang AU - Lingjuan He AU - Xiaoyang Lu AU - Qingwei Zhao AU - Tingbo Liang AU - Yunqing Qiu Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/05/2020.04.29.20085761.abstract N2 - Background Effective antiviral drugs for COVID-19 are still lacking. This study aims to evaluate the clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients.Methods Favipiravir and baloxavir acid were evaluated for their antiviral activity against SARS-CoV-2 in vitro before the trial initiation. We conducted an exploratory trial with 3 arms involving hospitalized adult patients with COVID-19. Patients were randomized assigned in a 1:1:1 ratio into baloxavir marboxil group, favipiravir group, and control group. The primary outcome was the percentage of subjects with viral negative by Day 14 and the time from randomization to clinical improvement. Virus load reduction, blood drug concentration and clinical presentation were also observed. The trial was registered with Chinese Clinical Trial Registry (ChiCTR 2000029544).Results Baloxavir showed antiviral activity in vitro with the half-maximal effective concentration (EC50) of 5.48 µM comparable to arbidol and lopinavir, but favipiravir didn’t demonstrate significant antiviral activity up to 100 µM. Thirty patients were enrolled. The percentage of patients who turned viral negative after 14-day treatment was 70%, 77%, and 100% in the baloxavir, favipiravir, and control group respectively, with the medians of time from randomization to clinical improvement was 14, 14 and 15 days, respectively. One reason for the lack of virological effect and clinical benefits may be due to insufficient concentrations of these drugs relative to their antiviral activities.Conclusions Our findings do not support that adding either baloxavir or favipiravir under the trial dosages to the existing standard treatment.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2000029544Funding StatementZhejiang Provincial Science and technology department key R & D plan emergency project (No. 2020c03123-8)Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe complete de-identified patient dataset, statistical plan, and consent forms will be made available on request to YQ Q (qiuyq{at}zju.edu.cn) 1 year after publication, with no time limit. ER -